Clinical Trial Update: Phase I Study of Docetaxel and 177-Lutetium-PSMA-I&T in First-Line Treatment for Patients With Metastatic Castration-Resistant Prostate Adenocarcinoma [Phase 1]

View source ↗

Summary

Phase I clinical trial evaluating the combination of Docetaxel and Lutetium-177 PSMA-I&T as first-line treatment for metastatic castration-resistant prostate ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• 177-Lutetium-PSMA-I&T (Lutetium-177 PSMA-I&T)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: Instituto do Cancer do Estado de São Paulo | Conditions: Prostate Cancer (Adenocarcinoma) | Phase 1 | Status: NOT_YET_RECRUITING